Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403649 | 0.81 | NOS3 (0.38) | CHRNA7BRD4CCR1CCR5CCR8 | |
| SCHEMBL21622427 | 0.80 | HSD17B10 (0.42) | CHRNA7BRD4 | |
| SCHEMBL31370721 | 0.78 | BRD4 (0.35) | BRD4CCR1CCR5CCR8NOS3 | |
| SCHEMBL18359212 | 0.78 | LRRK2 (0.38) | CHRNA7BRD4CCR1CCR5CCR8 | |
| SCHEMBL17211632 | 0.78 | BRD4 (0.55) | BRD4CCR1CCR5CCR8NOS3 | |
| SCHEMBL21440031 | 0.77 | CHRNA7 (0.35) | CHRNA7BRD4 | |
| SCHEMBL20413788 | 0.75 | ALDH1A1 (0.42) | BRD4KDM4EMTNR1A | |
| SCHEMBL18538061 | 0.75 | BRD4 (0.34) | BRD4KDM4E | |
| SCHEMBL17211630 | 0.74 | BRD4 (0.36) | BRD4CCR1CCR5CCR8 | |
| SCHEMBL20413789 | 0.74 | MTNR1A (0.41) | CHRNA7BRD4KDM4EMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202767-B1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2019-04-03 | — | — | EP | disclosed |
| US-20170296537-A1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2017-10-19 | — | — | US | disclosed |
| EP-3202767-A1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2017-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170296537-A1 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF | EGFR, ERBB2, ERBB4 | CHRNA7 4782/4885BRD4 4256/4885CCR1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.